Great progress has been made in many countries to tackle the HIV epidemic. A newly diagnosed patient with access to the latest antiretroviral therapy (ART) can hope to have a normal life expectancy. Yet, over 30 years since the emergence of the virus, and 29 years since the first World’s AIDS Day, much more needs to done to bring these advances to developing countries and to reach groups at high risk of HIV transmission. One of the biggest barriers to achieving this aim is the stigma that is still rife in many countries.
Seeking a cure for HIVSubscription
Efforts to find a cure for HIV were reinvigorated in 2008 when the case of Timothy Ray Brown showed that a cure is possible. Researchers and pharmaceutical companies are now seeking out the virus in its hiding places in an attempt to eradicate it completely.
The World Health Organization warns of increasing HIV drug resistance and issues new guidelines to address threatSubscription
Meg Caroline Doherty from the World Health Organization discusses the increasing number of cases HIV drug resistance, and the new guidelines and global action plan developed by the WHO to help countries address the threat.
HIV services need to evolve to meet new needsSubscription
A stronger, less fragmented system of HIV services is needed in order to keep pace with the changing needs of patients.
Limiting HIV resistance must not be neglected in an era where we continue to see breakthroughs in treatment for the infection once labelled a death sentence.
Unanswered questions about proposed PrEP trial Subscription
With 17 new HIV diagnoses made every day in the UK, we need to be bold and ambitious in our approach to HIV prevention — and this must include access to pre-exposure prophylaxis (PrEP) for all who need it.
For the first time since the beginning of the HIV epidemic more than 30 years ago a fall in the number of new HIV diagnoses among gay and bisexual men has been recorded, a Public Health England report has said
The US Food and Drug Administration has approved the first two-drug treatment regimen for the treatment of human immunodeficiency virus type 1 (HIV-1)
The world’s first national radio service for prisons is developing a project to reduce the stigma around HIV, following funding from the Department of Health.
A full statutory public inquiry will be held to examine how thousands of people were given contaminated blood transfusions during the 1970s and 1980s.
Study highlights a need for adolescent men who have sex with men to be given pre-exposure prophylaxis and for adherence to be promoted in this group.
A vaginal ring containing the antiretroviral drug dapivirine had high adherence among young women, study finds
Combining HIV vaccination with immune stimulation delayed viral rebound in monkeys with simian immunotherapy virus.
New target for HIV vaccine foundSubscription
The fusion peptide is a new region of interest for HIV vaccine development, researchers say.
Trial results show extended protection against HIV in monkeys treated with monoclonal antibodies.
HIV resistance to tenofovir surprisingly commonSubscription
Pharmacist Ana Martinez explains how involving pharmacists in HIV clinical trials earned her the highest honour from the International Pharmaceutical Federation.